Lung Cancer Mutation Analysis

肺癌突变分析

基本信息

批准号：
7944145
负责人：
PAUL A. BUNN
金额：
$ 234.53万
依托单位：
UNIVERSITY OF COLORADO DENVER
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
起止时间：
2009-09-29 至 2012-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7944145
关键词：
Accounting Adenocarcinoma BRAF gene Cancer Etiology Cancer Patient Cessation of life Classification Clinical Clinical Trials Clinical Trials Network Combination Drug Therapy Data Development Disease ERBB2 gene ERBB3 gene Enrollment Epidermal Growth Factor Receptor Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Equipment ErbB4 gene Europe Excision Frequencies Funding Funding Agency Future Genes Genetic screening method Genomics Goals Grant Institution KRAS2 gene Laboratories Lead Link Lung Adenocarcinoma MAP2K1 gene Malignant Neoplasms Malignant neoplasm of lung Medicine Methods Molecular Mutate Mutation Mutation Analysis Non-Small-Cell Lung Carcinoma Oncogenes Online Systems Operative Surgical Procedures Oral Outcome PIK3CA gene Pathologic Pathology Patients Positioning Attribute Progression-Free Survivals Protocols documentation Radiation therapy Reagent Research Research Infrastructure Series Signal Pathway Specimen Staging Testing Therapeutic Agents Therapy Clinical Trials Time Tissue Banks Tissues Toxic effect Tumor Tissue Woman abstracting advanced disease base cancer genomics chemotherapy cost experience fusion gene genetic analysis inhibitor/antagonist interest intravenous administration meetings member men new technology novel novel therapeutics operation outcome forecast prognostic prototype response tumor

项目摘要

DESCRIPTION (provided by applicant): Abstract this project aims to establish a Lung Cancer Mutation Consortium (LCMC) consisting of 13 institutions with a major interest in lung cancer and genomic testing of lung cancer as documented by having major NCI grants in lung cancer. The LCMC members will collect linked clinical, pathologic and genomic data on 1000 patients with advanced adenocarcinoma of the lung in the proposed clinical trial. The genomic tests will be conducted in CLIA certified laboratories located at consortium institutions according to consortium protocols. The protocol will determine the frequency of each genetic change; the association between the genetic change, the clinical features, and the outcome; and the association between different genetic changes. The information will be used to validate and/or change the pathologic sub-classification of adenocarcinomas. The genetic analyses will be used to determine if patients with specific genetic changes are eligible for enrollment into therapeutic trials evaluating novel targeted therapies directed at the specific mutation / amplification / fusion gene. These therapeutic trials are funded by other mechanisms. The proposal will lead to the creation of at least 16 new positions and to the purchase of equipment and reagents for the genetic testing. The trial results and the establishment of the LCMC will hasten the implementation of personalized medicine for lung cancer. PUBLIC HEALTH RELEVANCE: Relevance Lung cancer is the leading cause of cancer death in men and women in the U.S., accounting for about 30% of all cancer deaths. About half of all lung cancer patients present with advanced disease for which standard chemotherapy combinations produce only modest survival improvement with the associated high toxicity rates, inconvenience of intravenous administration and high costs. Recent molecular studies showed that as many as 50% of lung cancer have activating mutations in known oncogenes to which novel therapeutic agents have been developed. Early clinical trials suggest that targeted oral agents have less toxicity and greater benefit than chemotherapy but only when administered to patients with the specific mutated oncogene. The new technologies in this application will allow a large number of lung cancer patients to have molecular tests for these newly described oncogenes so that we can understand their frequency, relevance and importance as predictors to benefit from the new targeted agents. This proposal will hasten the development of personalized medicine for lung cancer and other cancers as well.

描述（由申请人提供）：摘要该项目旨在建立一个肺癌突变联盟 (LCMC)，由 13 个对肺癌和肺癌基因组测试有重大兴趣的机构组成，这些机构在肺癌方面拥有主要的 NCI 资助。 LCMC 成员将在拟议的临床试验中收集 1000 名晚期肺腺癌患者的相关临床、病理和基因组数据。基因组测试将根据联盟协议在位于联盟机构的 CLIA 认证实验室进行。该方案将确定每个基因变化的频率；遗传变化、临床特征和结果之间的关联；以及不同基因变化之间的关联。该信息将用于验证和/或改变腺癌的病理亚分类。遗传分析将用于确定具有特定遗传变化的患者是否有资格参加治疗试验，评估针对特定突变/扩增/融合基因的新型靶向疗法。这些治疗试验由其他机制资助。该提案将导致创建至少 16 个新职位，并购买用于基因检测的设备和试剂。试验结果和LCMC的成立将加速肺癌个体化医疗的实施。公共卫生相关性：相关性肺癌是美国男性和女性癌症死亡的主要原因，约占所有癌症死亡的 30%。大约一半的肺癌患者患有晚期疾病，标准化疗组合只能产生适度的生存改善，同时伴随着高毒性率、静脉注射的不便和高成本。最近的分子研究表明，多达 50% 的肺癌在已知癌基因中存在激活突变，针对这些突变已开发出新的治疗药物。早期临床试验表明，靶向口服药物比化疗具有更低的毒性和更大的益处，但仅限于针对具有特定突变癌基因的患者。该应用中的新技术将使大量肺癌患者能够对这些新描述的癌基因进行分子测试，以便我们能够了解它们的频率、相关性和重要性，作为从新的靶向药物中受益的预测因子。该提案将加速肺癌和其他癌症个体化医疗的发展。